AT398166B - Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung von nitrofurantoin (-salzen, -hydraten, -komplexen) - Google Patents
Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung von nitrofurantoin (-salzen, -hydraten, -komplexen) Download PDFInfo
- Publication number
- AT398166B AT398166B AT0151687A AT151687A AT398166B AT 398166 B AT398166 B AT 398166B AT 0151687 A AT0151687 A AT 0151687A AT 151687 A AT151687 A AT 151687A AT 398166 B AT398166 B AT 398166B
- Authority
- AT
- Austria
- Prior art keywords
- nitrofurantoin
- capsule
- particulate mixture
- particulate
- mixture
- Prior art date
Links
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 title claims description 139
- 229960000564 nitrofurantoin Drugs 0.000 title claims description 134
- 239000002775 capsule Substances 0.000 title claims description 119
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 150000004677 hydrates Chemical class 0.000 title claims description 7
- 150000003839 salts Chemical class 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 claims description 120
- 229920002125 Sokalan® Polymers 0.000 claims description 48
- 230000003111 delayed effect Effects 0.000 claims description 41
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 39
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 37
- 238000013268 sustained release Methods 0.000 claims description 32
- 239000012730 sustained-release form Substances 0.000 claims description 32
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 20
- 239000002552 dosage form Substances 0.000 claims description 17
- 239000013078 crystal Substances 0.000 claims description 13
- 210000004051 gastric juice Anatomy 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 238000011049 filling Methods 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 239000007903 gelatin capsule Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000000454 talc Substances 0.000 claims description 9
- 229910052623 talc Inorganic materials 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 230000002496 gastric effect Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 229940090037 macrodantin Drugs 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000012738 dissolution medium Substances 0.000 claims 4
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 238000007922 dissolution test Methods 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000004804 winding Methods 0.000 claims 1
- 239000010410 layer Substances 0.000 description 20
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 206010047700 Vomiting Diseases 0.000 description 9
- 206010028813 Nausea Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000008693 nausea Effects 0.000 description 8
- 208000019206 urinary tract infection Diseases 0.000 description 8
- 230000001427 coherent effect Effects 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 229920005862 polyol Polymers 0.000 description 7
- 150000003077 polyols Chemical class 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 239000011149 active material Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000009969 flowable effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000416 hydrocolloid Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229920000570 polyether Polymers 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical group C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- -1 Poly [1- (2-oxo-1-pyrrolidinyl) ethylene] Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- WQINSVOOIJDOLJ-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetic acid Chemical compound C1=CC=C2C(=O)N(CC(=O)O)C(=O)C2=C1 WQINSVOOIJDOLJ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- AFDJQFFKYDCYIG-JSGFVSQVSA-M sodium;3-[(e)-(5-nitrofuran-2-yl)methylideneamino]-5-oxo-4h-imidazol-2-olate Chemical compound [Na+].[O-]C1=NC(=O)CN1\N=C\C1=CC=C([N+]([O-])=O)O1 AFDJQFFKYDCYIG-JSGFVSQVSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/874,943 US4772473A (en) | 1986-06-16 | 1986-06-16 | Nitrofurantoin dosage form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ATA151687A ATA151687A (de) | 1994-02-15 |
| AT398166B true AT398166B (de) | 1994-10-25 |
Family
ID=25364916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT0151687A AT398166B (de) | 1986-06-16 | 1987-06-15 | Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung von nitrofurantoin (-salzen, -hydraten, -komplexen) |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4772473A (ja) |
| EP (1) | EP0250023B1 (ja) |
| JP (1) | JP2509226B2 (ja) |
| AT (1) | AT398166B (ja) |
| AU (1) | AU592731B2 (ja) |
| CA (1) | CA1288050C (ja) |
| DE (1) | DE3772113D1 (ja) |
| DK (1) | DK173432B1 (ja) |
| IE (1) | IE60661B1 (ja) |
| IL (1) | IL82807A (ja) |
| NZ (1) | NZ220695A (ja) |
| PH (1) | PH22843A (ja) |
| ZA (1) | ZA874316B (ja) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4917892A (en) * | 1988-06-28 | 1990-04-17 | Temple University | Encapsulated topical delivery system |
| US5178880A (en) * | 1989-07-25 | 1993-01-12 | Norwich Eaton Pharmaceuticals, Inc. | Liquid suspensions of nitrofurantoin |
| US5332832A (en) * | 1989-07-26 | 1994-07-26 | Procter & Gamble Pharmaceuticals, Inc. | Nitrofurantoin crystals |
| US5360402A (en) * | 1990-01-10 | 1994-11-01 | Rochester Medical Corporation | Hand-actuated retention catheter |
| US5261896A (en) * | 1990-01-10 | 1993-11-16 | Rochester Medical Corporation | Sustained release bactericidal cannula |
| US5670111A (en) * | 1990-01-10 | 1997-09-23 | Rochester Medical Corporation | Method of shaping structures with an overcoat layer including female urinary catheter |
| US6626888B1 (en) | 1990-01-10 | 2003-09-30 | Rochester Medical Corporation | Method of shaping structures with an overcoat layer including female urinary catheter |
| US5269770A (en) * | 1990-01-10 | 1993-12-14 | Rochester Medical Corporation | Microcidal agent releasing catheter with balloon |
| US5971954A (en) * | 1990-01-10 | 1999-10-26 | Rochester Medical Corporation | Method of making catheter |
| AU769224B2 (en) * | 1998-12-28 | 2004-01-22 | Taisho Pharmaceutical Co., Ltd. | External preparation |
| US6660303B2 (en) * | 1999-12-06 | 2003-12-09 | Edward Mendell & Co. | Pharmaceutical superdisintegrant |
| KR20040018394A (ko) * | 2001-07-04 | 2004-03-03 | 썬 파마슈티컬 인더스트리스 리미티드 | 위 정체 제어되는 약물 전달 계 |
| MY142204A (en) * | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
| MXPA05002136A (es) * | 2002-08-23 | 2005-06-03 | Ranbaxy Lab Ltd | Forma de dosificacion de liberacion controlada de nitrofurantoina. |
| US20050202079A1 (en) * | 2004-03-15 | 2005-09-15 | Mylan Pharmaceuticals Inc. | Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation |
| NZ553645A (en) | 2004-08-13 | 2010-09-30 | Boehringer Ingelheim Int | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| CN101005830B (zh) * | 2004-08-13 | 2010-09-29 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放片剂、其制备方法及用途 |
| US8864730B2 (en) | 2005-04-12 | 2014-10-21 | Rochester Medical Corporation | Silicone rubber male external catheter with absorbent and adhesive |
| US20080095844A1 (en) * | 2006-10-23 | 2008-04-24 | Rajhans Sujay Kamalakar | Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof |
| US8603200B2 (en) * | 2009-06-22 | 2013-12-10 | Afton Chemical Corporation | Compositions comprising combustion improvers and methods of use thereof |
| CN102000041A (zh) * | 2010-11-19 | 2011-04-06 | 合肥合源药业有限公司 | 含有速释和缓释两种成分的呋喃坦啶胶囊及其制备方法 |
| US9707375B2 (en) | 2011-03-14 | 2017-07-18 | Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. | Catheter grip and method |
| US10092728B2 (en) | 2012-11-20 | 2018-10-09 | Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. | Sheath for securing urinary catheter |
| US9872969B2 (en) | 2012-11-20 | 2018-01-23 | Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. | Catheter in bag without additional packaging |
| AU2015306630B2 (en) | 2014-08-26 | 2018-12-13 | C.R. Bard, Inc | Urinary catheter |
| CA3070865A1 (en) | 2017-09-19 | 2019-03-28 | C.R. Bard, Inc. | Urinary catheter bridging device, systems and methods thereof |
| EP4285895A1 (en) * | 2022-06-03 | 2023-12-06 | Adalvo Limited | Nitrofurantoin oral dosage form |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2100921A1 (ja) * | 1970-07-17 | 1972-03-24 | Scherer Corp R P | |
| FR2407720A1 (fr) * | 1977-11-08 | 1979-06-01 | Lipha Lyonnaise Indle Pharmace | Preparations pharmaceutiques orales a activite therapeutique prolongee |
| US4247552A (en) * | 1979-01-11 | 1981-01-27 | Syntex (U.S.A.) Inc. | Contraceptive compositions and methods employing 1-substituted imidazole derivatives |
| US4370313A (en) * | 1981-10-26 | 1983-01-25 | Eaton Laboratories, Inc. | Nitrofurantoin dosage form |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL171628C (nl) * | 1950-05-29 | Inst Francais Du Petrole | Inrichting voor het uitzenden van akoestische golven in een vloeibaar milieu. | |
| US3401221A (en) * | 1964-08-25 | 1968-09-10 | Norwich Pharma Co | Treatment of urinary tract infection |
| US3427378A (en) * | 1965-02-12 | 1969-02-11 | American Cyanamid Co | Sustained release encapsulated formula |
| GB1093286A (en) * | 1965-02-15 | 1967-11-29 | Biorex Laboratories Ltd | Improvements in or relating to dosage unit forms for the administration of medicaments and diagnostic agents |
| US3458622A (en) * | 1967-04-07 | 1969-07-29 | Squibb & Sons Inc | Controlled release tablet |
| GB1204580A (en) * | 1968-10-05 | 1970-09-09 | Aspro Nicholas Ltd | Pharmaceutical dosage forms |
| US3634584A (en) * | 1969-02-13 | 1972-01-11 | American Home Prod | Sustained action dosage form |
| US4152444A (en) * | 1972-04-19 | 1979-05-01 | Ciba-Geigy Corporation | Pharmaceutical compound preparations with bactericidal action |
| US4016254A (en) * | 1972-05-19 | 1977-04-05 | Beecham Group Limited | Pharmaceutical formulations |
| US4126672A (en) * | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
| US4122157A (en) * | 1977-03-04 | 1978-10-24 | Richardson-Merrell Inc. | Nitrofurantoin sustained release tablet |
| FR2403080A1 (fr) * | 1977-09-15 | 1979-04-13 | Heyden Chem Fab | Preparation de nitrofurantoine a effet retard pour administration orale et son procede de fabrication |
| CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4252786A (en) * | 1979-11-16 | 1981-02-24 | E. R. Squibb & Sons, Inc. | Controlled release tablet |
| FR2525108B1 (fr) * | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
| US4798725A (en) * | 1986-06-16 | 1989-01-17 | Norwich Eaton Pharmaceuticals, Inc. | Sustained release capsule |
-
1986
- 1986-06-16 US US06/874,943 patent/US4772473A/en not_active Expired - Lifetime
-
1987
- 1987-06-04 EP EP87201051A patent/EP0250023B1/en not_active Expired - Lifetime
- 1987-06-04 DE DE8787201051T patent/DE3772113D1/de not_active Expired - Lifetime
- 1987-06-08 IL IL82807A patent/IL82807A/xx not_active IP Right Cessation
- 1987-06-15 AU AU74211/87A patent/AU592731B2/en not_active Expired
- 1987-06-15 AT AT0151687A patent/AT398166B/de not_active IP Right Cessation
- 1987-06-15 IE IE158587A patent/IE60661B1/en not_active IP Right Cessation
- 1987-06-15 CA CA000539706A patent/CA1288050C/en not_active Expired - Lifetime
- 1987-06-15 NZ NZ220695A patent/NZ220695A/xx unknown
- 1987-06-15 PH PH35401A patent/PH22843A/en unknown
- 1987-06-16 DK DK198703064A patent/DK173432B1/da not_active IP Right Cessation
- 1987-06-16 JP JP62150048A patent/JP2509226B2/ja not_active Expired - Lifetime
- 1987-06-16 ZA ZA874316A patent/ZA874316B/xx unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2100921A1 (ja) * | 1970-07-17 | 1972-03-24 | Scherer Corp R P | |
| FR2407720A1 (fr) * | 1977-11-08 | 1979-06-01 | Lipha Lyonnaise Indle Pharmace | Preparations pharmaceutiques orales a activite therapeutique prolongee |
| US4247552A (en) * | 1979-01-11 | 1981-01-27 | Syntex (U.S.A.) Inc. | Contraceptive compositions and methods employing 1-substituted imidazole derivatives |
| US4370313A (en) * | 1981-10-26 | 1983-01-25 | Eaton Laboratories, Inc. | Nitrofurantoin dosage form |
Also Published As
| Publication number | Publication date |
|---|---|
| DK173432B1 (da) | 2000-10-23 |
| DK306487D0 (da) | 1987-06-16 |
| IL82807A (en) | 1991-12-12 |
| ZA874316B (en) | 1988-08-31 |
| AU7421187A (en) | 1987-12-17 |
| ATA151687A (de) | 1994-02-15 |
| IE871585L (en) | 1987-12-16 |
| EP0250023B1 (en) | 1991-08-14 |
| DK306487A (da) | 1987-12-17 |
| JP2509226B2 (ja) | 1996-06-19 |
| NZ220695A (en) | 1990-08-28 |
| DE3772113D1 (de) | 1991-09-19 |
| IL82807A0 (en) | 1987-12-20 |
| PH22843A (en) | 1989-01-19 |
| AU592731B2 (en) | 1990-01-18 |
| CA1288050C (en) | 1991-08-27 |
| EP0250023A1 (en) | 1987-12-23 |
| US4772473A (en) | 1988-09-20 |
| IE60661B1 (en) | 1994-08-10 |
| JPS63258420A (ja) | 1988-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT398166B (de) | Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung von nitrofurantoin (-salzen, -hydraten, -komplexen) | |
| AT398165B (de) | Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung mit verzögerter wirkstofffreisetzung bzw. kombinierter verzögerter/rascher wirkstofffreisetzung | |
| DE69629797T2 (de) | Matrix zur gesteuerten freisetzung von arzneistoffen | |
| DE69821553T2 (de) | Granulatzubereitung enthaltend Simethicon und granuliertes wasserfreies Calciumphosphat | |
| DE60103299T2 (de) | Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe | |
| DE69434640T2 (de) | Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe | |
| EP0068191B2 (de) | Orale Dipyridamolformen | |
| DE69230112T2 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
| DE69205971T2 (de) | Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten. | |
| DE69431247T2 (de) | Oxybutyninformulierungen mit gesteuerter freisetzung | |
| DE69110969T2 (de) | Verwendung von Triclosan zur Behandlung von Krankheiten des Gastrointestinaltraktes. | |
| DE60019116T2 (de) | Neue omeprazole und (s)-omeprazole zusammensetzung | |
| DE69618934T2 (de) | Verbesserte organische zusammensetzungen | |
| DE69913197T2 (de) | Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe | |
| DE69020758T2 (de) | Die Wirkstoffabgabe steuerndes Überzugsmaterial für lang wirksame Formulierungen. | |
| DE3024858A1 (de) | Anhaltend freigebende pharmazeutische zubereitung eines festen medikamentmaterials | |
| DE2611041A1 (de) | Retard-formulierung | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| EP1509207B1 (de) | Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung | |
| DE3879111T2 (de) | Pharmazeutische kautablette mit geschmaksmaskierung. | |
| DE69111574T2 (de) | Polycarbophil-Kalzium enthaltendes Arzneimittel. | |
| DE60006362T2 (de) | Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen | |
| DE69008107T2 (de) | Zubereitung mit verzögerter Freigabe eines Hydrochlorids eines basischen Arzneistoffs. | |
| DE69526434T2 (de) | Metronidazolpräparate mit modifizierter freisetzung und verfahren für ihre herstellung und verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EFA | Change in the company name | ||
| UEP | Publication of translation of european patent specification | ||
| ELA | Expired due to lapse of time |